Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: BSGrinder who wrote (58819)	5/7/1999 5:29:00 PM
From: Knighty Tin	Respond to of 132070

Kit, Merritt will disagree, but I think SangStat is a good spec. We knew from day one that Novartis would sue them and I mentioned it here two years ago. But they also have lawyers and they know patent law, and they have taken many steps to differentiate from Neoral. So, I think we have a lot of huffing and puffing, but Sang starts to sell 20% under Novaris's price. And in this billion dollar market growing at 40% a year, that could mean some good money for an $11 stock. I have no idea about the spike earlier in the week. Never heard any news or even rumors on it.